News

Studying MS lesions in brain tissue gives clues into genes

1 March 2016

Although many risk factors for MS have been identified, the exact causes and triggers for the disease are not yet known. A great deal of research has been dedicated to understanding the mechanisms of lesion formation and the potential external triggers that may underlie MS onset.

Undergraduate student Mr Adam Girardin recently received a MS Research Australia Vacation Scholarship to undertake a ten-week laboratory internship under the supervision of Dr Simon Willis at the Walter and Eliza Hall Institute of Medical Research in Melbourne, to further study the interaction between gene expression and MS lesions.

In the first phase of this project, Mr Girardin aims to study the early changes in gene activity that are associated with MS lesion formation. He will be using post-mortem brain tissue donated to the Multiple Sclerosis Society Tissue Bank at Imperial College London in the UK. During his scholarship Mr Girardin will be completing a series of experiments, looking to follow-up on earlier work in Dr Willis’ laboratory that identified changes in the way genes are decoded by cells in the brain that may trigger the formation of lesions. The second aim of Mr Girardin’s project is to identify whether any infectious agents are present in the brain tissue samples that may be contributing to MS onset or MS risk, and if so, to better understand how the immune system responds and how this may affect the brain.

Vacation scholarships allow promising young students to kick start their training in research and starts them on a pathway to join the growing ranks of researchers working on the problems of MS. This particular type of research that Mr Girardin will be undertaking, helps to enhance our understanding of MS disease development and could identify genes that may be useful targets for developing new treatments. This type of work is not possible without the generosity of people with MS who have donated their brain to MS Brain Banks around the world.

To find out more about the MS Research Australia Brain Bank, phone 1300 672 265 or register here.

 

Related News

MS News

Thank you! Ocrevus and Kesimpta will remain on the PBS

17 July 2026

The Australian Government has confirmed that Ocrevus and Kesimpta will remain available through the Pharmaceutical Benefits Scheme (PBS), meaning thousands of Australians living with MS can continue to access these life-changing treatments. 

MS News

MS Australia applauds Health Minister’s announcement that Ocrevus and Kesimpta will remain on the PBS

16 July 2026

MS Australia warmly welcomes the announcement from the Minister for Health and Aged Care, the Hon Mark Butler MP, that Ocrevus (ocrelizumab) and Kesimpta (ofatumumab) will remain available through the Pharmaceutical Benefits Scheme (PBS).

MS News

PBS access to two vital MS treatments under threat as Government decision looms

1 July 2026

Multiple disease-modifying therapies (DMTs), Ocrevus (ocrelizumab) and Kesimpta (ofatumumab), are at risk of being withdrawn from the Pharmaceutical Benefits Scheme (PBS), as a consequence of government-driven policy-related price reductions.

Read More

Newsletter subscription

  • This field is for validation purposes and should be left unchanged.

Studying MS lesions in brain tissue gives clues into genes